Allergan PLC. (AGN) Receives Hold Rating from Cantor Fitzgerald
“Allergan announced mixed top-line results from its Phase 2b study of CVC for NASH. The Street was waiting for this, and the delay relative to Street expectations had been one reason the stock has been weak.”,” Cantor Fitzgerald’s analyst commented.
Several other equities analysts have also weighed in on AGN. BidaskClub lowered Allergan PLC. from a buy rating to a hold rating in a research note on Wednesday, August 9th. UBS AG reissued an outperform rating and issued a $275.00 target price on shares of Allergan PLC. in a research note on Wednesday, August 9th. Wells Fargo & Company reissued an outperform rating and issued a $280.00 target price (up previously from $270.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. Argus reissued a buy rating and issued a $280.00 target price on shares of Allergan PLC. in a research note on Monday, August 14th. Finally, Deutsche Bank AG reissued a buy rating and issued a $278.00 target price (up previously from $273.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. One analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company’s stock. Allergan PLC. currently has a consensus rating of Buy and an average price target of $272.94.
Allergan PLC. (NYSE AGN) opened at 211.60 on Friday. The company has a 50-day moving average price of $229.79 and a 200-day moving average price of $236.07. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The stock has a market cap of $70.74 billion, a PE ratio of 6.45 and a beta of 1.18.
Allergan PLC. (NYSE:AGN) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. During the same quarter in the prior year, the firm posted $3.35 earnings per share. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. Analysts anticipate that Allergan PLC. will post $16.22 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Allergan PLC. (AGN) Receives Hold Rating from Cantor Fitzgerald” was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.watchlistnews.com/allergan-plc-agn-receives-hold-rating-from-cantor-fitzgerald/1587982.html.
The business also recently declared a quarterly dividend, which was paid on Friday, September 15th. Shareholders of record on Friday, August 18th were paid a $0.70 dividend. The ex-dividend date was Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.37%. Allergan PLC.’s dividend payout ratio is 9.95%.
A number of hedge funds have recently bought and sold shares of the business. Ardsley Advisory Partners bought a new position in Allergan PLC. in the second quarter valued at approximately $486,000. Intl Fcstone Inc. bought a new position in Allergan PLC. in the second quarter valued at approximately $1,626,000. Phocas Financial Corp. bought a new position in Allergan PLC. in the second quarter valued at approximately $150,000. Sentry Investment Management LLC grew its stake in Allergan PLC. by 1.0% in the second quarter. Sentry Investment Management LLC now owns 26,889 shares of the company’s stock valued at $6,536,000 after purchasing an additional 265 shares in the last quarter. Finally, WFG Advisors LP grew its stake in Allergan PLC. by 20.9% in the second quarter. WFG Advisors LP now owns 793 shares of the company’s stock valued at $193,000 after purchasing an additional 137 shares in the last quarter. Hedge funds and other institutional investors own 82.02% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.